TickerFacts.

Company research / EBS

Emergent BioSolutions Inc. (EBS)

Build a valuation ↗↓ Download CSV

CIK 0001367644 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Emergent BioSolutions Inc. reported revenue of $742.90M. Revenue fell 28.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $770.20M.

Key ratios (year ended 2025-12-31)

56.1%
Gross margin (computed)
13.5%
Operating margin
7.1%
Net margin
10.1%
Return on year-end equity
-28.8%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$770.20M$742.90M$1.04B$1.05B$1.12B$1.77B$1.58B$1.11Bn/an/an/a
Cost of Revenue$339.90M$326.20M$681.30M$705.40M$693.10M$748.10M$537.00M$433.50M$322.30M$187.70M$126.30M
Gross Profit (computed)$430.30M$416.70M$362.30M$343.90M$424.40M$1.03B$1.04B$672.50Mn/an/an/a
R&D Expense$45.30M$53.20M$70.70M$111.40M$188.30M$235.20M$237.90M$226.20M$142.80M$97.40M$106.90M
Operating Income-$66.00M$100.10M-$108.70M-$726.40M-$170.00M$341.40M$438.50M$114.10M$89.80M$124.30M$105.50M
Depreciation & Amortization$94.40M$95.80M$108.80M$125.10M$143.30M$123.80M$50.10M$49.50M$36.30M$32.20M$28.02M
EBITDA$28.40M$195.90M$100.0K-$601.30M-$26.70M$465.20M$488.60M$163.60M$126.10M$156.50M$133.52M
Net Income-$176.80M$52.60M-$190.60M-$760.50M-$211.60M$219.50M$305.80M$54.50M$62.70M$82.60M$51.80M
EPS (Diluted)n/a$0.93-$3.60-$14.85-$4.22$4.06$5.68$1.04$1.22$1.71$1.13
Total Assets$1.12B$1.32B$1.39B$1.82B$3.17B$2.96B$2.88B$2.33B$2.23B$1.07B$970.11M
Total Liabilities$775.40M$796.00M$906.90M$1.17B$1.78B$1.35B$1.44B$1.24B$1.22B$157.90M$373.91M
Long-Term Debt$589.70M$589.70M$700.00M$868.40M$1.41B$849.60M$885.50M$822.50M$808.80M$13.60Mn/a
Shareholders' Equity$341.40M$522.60M$482.80M$649.30M$1.39B$1.61B$1.45B$1.09B$1.01B$912.30Mn/a
Cash & Equivalents$139.70M$205.40M$99.50M$111.70M$642.60M$576.10M$621.30M$167.80M$112.20M$178.30M$271.50M
Operating Cash Flow$97.70M$170.60M$58.70M-$206.30M-$34.10M$320.20M$536.90M$188.00M$41.80M$208.10M$54.60M
Capital Expenditures$11.80M$13.80M$22.90M$51.60M$115.80M$224.10M$141.90M$86.90M$72.10M$54.80M$76.20M
Free Cash Flow$85.90M$156.80M$35.80M-$257.90M-$149.90M$96.10M$395.00M$101.10M-$30.30M$153.30M-$21.60M
Share Repurchases$36.00M$24.90M$0$0$82.10M$106.00M$0$0$100.0K$33.10M$0
Shares Outstanding51.30M52.10M54.30M52.20M50.10M51.30M53.10M51.70M51.20M49.40M40.57M
Weighted Average Diluted Sharesn/a56.70M53.00M51.20M50.10M54.10M53.80M52.40M51.40M50.30M49.30M
EPS (Basic)n/a$0.98-$3.60-$14.85-$4.22$4.10$5.80$1.06$1.25$1.98$1.29

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView